Streetbeat News

NGNE

Neurogene Inc.

https://www.neurogene.com

Industry

Biotechnology

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

HC Wainwright & Co. has maintained a Buy rating on Neurogene (NASDAQ:NGNE) but lowered the price target from $51 to $49.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 10:37 am

Neurogene (NASDAQ:NGNE) reported a Q2 2024 GAAP EPS of $(1.09), missing the analyst consensus estimate of $(1.06) by 2.83%.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 11:35 am

Neurogene's NGN-401 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for the treatment of Rett Syndrome. This designation is expected to expedite the development and review process of NGN-401, potentially bringing a new treatment option to market faster.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:36 am

Neurogene (NGNE) will be added to the Russell 3000 Index, effective at the market open on July 1.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 11:35 am

Neurogene shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and announced a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 4:35 pm

BMO Capital has initiated coverage on Neurogene (NASDAQ:NGNE) with an Outperform rating and a price target of $65.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 9:17 am

The article highlights the pre-market movements of 12 healthcare stocks on Thursday. Tempest Therapeutics, Neurogene, Geovax Labs, SAB Biotherapeutics, Trevena, and Molecular Partners saw significant gains, while Mustang Bio, Mobile-health Network, Cyclerion Therapeutics, INmune Bio, CNS Pharma, and Praxis Precision Medicine experienced notable declines.

Portfolio Pulse from Benzinga Insights

June 20, 2024 | 12:06 pm

HC Wainwright & Co. has reiterated its Buy rating on Neurogene (NASDAQ:NGNE) and maintained a price target of $51.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 10:36 am

Quantum Corporation (NASDAQ:QMCO) shares fell 44.5% to $0.43 after reporting worse-than-expected FY24 financial results and issuing FY25 guidance below estimates. Other notable stock movements include Reliance Global Group (NASDAQ:RELI) jumping 350% after an acquisition update, and DermTech, Inc. (NASDAQ:DMTK) falling 58.4% after filing for Chapter 11 protection.

Portfolio Pulse from Avi Kapoor

June 18, 2024 | 5:39 pm

Neurogene shares are trading lower after the company announced that the first patient in Cohort 2 received high-dose NGN-401 gene therapy in the Phase 1/2 trial for female pediatric patients with Rett syndrome.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 2:57 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.